{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:24:02Z","timestamp":1784543042000,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1208\/s12248-019-0363-5","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T17:02:49Z","timestamp":1563555769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective"],"prefix":"10.1208","volume":"21","author":[{"given":"Youwei","family":"Bi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyn E.","family":"Epps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"363_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35\u201345.","journal-title":"Arthritis Rheum"},{"key":"363_CR2","unstructured":"Drug label for adalimumab BLA 125057, Oct 16 2018 <\n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125057s409lbl.pdf\n                    \n                  >."},{"key":"363_CR3","unstructured":"Humira : EPAR- Product Information. Aug 2018."},{"key":"363_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GB Jemec","year":"2012","unstructured":"Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158\u201364.","journal-title":"N Engl J Med"},{"key":"363_CR5","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.jid.2018.04.001","volume":"138","author":"A Garg","year":"2018","unstructured":"Garg A, Wertenteil S, Baltz R, Strunk A, Finelt N. Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis. J Invest Dermatol. 2018;138:2152\u20136.","journal-title":"J Invest Dermatol"},{"key":"363_CR6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cpt.1363","volume":"105","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhu H, Madabushi R, Liu Q, Huang SM, Zineh I. Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther. 2019;105:899\u2013911.","journal-title":"Clin Pharmacol Ther"},{"key":"363_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/annonc\/mdz037","volume":"30","author":"Y Bi","year":"2019","unstructured":"Bi Y, Liu J, Furmanski B, Zhao H, Yu J, Osgood C, et al. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann Oncol. 2019;30:644\u201351.","journal-title":"Ann Oncol"},{"key":"363_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422\u201334.","journal-title":"N Engl J Med"},{"key":"363_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/jdv.13216","volume":"30","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30:989\u201394.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"363_CR10","unstructured":"Yao LP. Extrapolation in pediatric drug development: an evolving science. 2018 ASA biopharmaceutical section regulatory-industry statistics workshop. Sep 2018."},{"key":"363_CR11","unstructured":"Guidance for industry: how to comply with the pediatric research equity act. Draft Guidance. Sep 2005."},{"key":"363_CR12","unstructured":"Federal Food, Drug, and Cosmetic Act (FD&C Act) U.S. Food and Drug Administration."},{"key":"363_CR13","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.jaad.2015.07.051","volume":"73","author":"C Liy-Wong","year":"2015","unstructured":"Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73:S36\u201341.","journal-title":"J Am Acad Dermatol"},{"key":"363_CR14","unstructured":"FDA clinical pharmacology and biopharmaceutic review: treatment of active moderate to severe hidradenitis suppurativa in adult patients. 2015."},{"key":"363_CR15","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/apt.13964","volume":"45","author":"S Van Steenbergen","year":"2017","unstructured":"Van Steenbergen S, Bian S, Vermeire S, Van Assche G, Gils A, Ferrante M. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn\u2019s disease - a nested case-control study. Aliment Pharmacol Ther. 2017;45:923\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"363_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/MIB.0000000000000715","volume":"22","author":"MC Dubinsky","year":"2016","unstructured":"Dubinsky MC, Rosh J, Faubion WA Jr, Kierkus J, Ruemmele F, Hyams JS, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2016;22:886\u201393.","journal-title":"Inflamm Bowel Dis"},{"key":"363_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","volume":"19","author":"C Ryan","year":"2018","unstructured":"Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19:437\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"363_CR18","unstructured":"2 to 20 years: Boys, Stature-for-age and Weight-for-age percentiles. Centers for Disease Control and Prevention."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-019-0363-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-019-0363-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:06:12Z","timestamp":1595027172000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-019-0363-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1208\/s12248-019-0363-5","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"22 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All listed authors are employees of the Food and Drug Administration of the United States. The authors indicated no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The views expressed in this article are those of the authors and do not necessarily reflect the official views of the FDA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"91"}}